Transfer Point is honored to contribute to the clinical research and development of Beta Glucan by donating our premium products to scientists and institutions for study.
Columbia, SC (PRWEB) June 12, 2013
Transfer Point Inc. is pleased to report that it donated its Glucan 300® dietary supplement product to the University of Louisville, Kentucky for a blinded, placebo controlled clinical study conducted by Dr. Vaclav Vetvicka. The focus of the study was on the immune impact of Beta Glucan. The results were positive and encouraging enough to add to the body of evidence that strongly supports Beta Glucan’s role supporting the immune system.
Marilyn Becker, CEO stated, “Transfer Point is honored to contribute to the clinical research and development of Beta Glucan by donating our premium products to scientists and institutions for study. We know Beta Glucan can play an important role in supporting good health and this study helps adds to that body of evidence.”
A.J. Lanigan, a 17-year veteran in the beta glucan industry stated, “I am quite pleased to see how interest in the Glucan 300® product has grown over the years. To see researchers in universities and teaching hospitals continue to produce new science in recognized journals certainly goes a long way to clear confusion about glucans.” Lanigan goes on to caution, “While the study is promising, more research needs to be conducted on Beta Glucan to determine whether to develop a drug product for specific and targeted market. We intend to be part of that ongoing research. Right now we are content in being contributors to good scientific evaluation of the potential of Beta Glucan. Our products are not intended for people with disease conditions, who should be under the care and supervision of licensed health professionals. Beta Glucan products are not substitutes for drug products.”
Transfer Point is a privately held corporation in business for more than 14 years and produces and sells premium Beta Glucan products for people who wish to maintain good health. http://www.transferpoint.com
View the abstract: http://thescipub.com/abstract/10.3844/ajisp.2013.43.47
Transfer Point, Inc.